Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | PIM2 | Q9P1W9 | 10/20 | 0.42 |
| ▸ | PIM3 | Q86V86 | 9/20 | 0.42 |
| ▸ | PIM1 | P11309 | 6/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.41 |
| ▸ | CDC42BPB | Q9Y5S2 | 4/20 | 0.41 |
| ▸ | CDC42BPA | Q5VT25 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11906992 | 0.84 | PIM2 (0.56) | PIM2PIM3PIM1ROCK2ROCK1 | |
| SCHEMBL11908053 | 0.84 | PIM2 (0.56) | PIM2PIM3PIM1ROCK2ROCK1 | |
| SCHEMBL20189967 | 0.83 | MAPT (0.54) | MAPTPIM2PIM3PIM1ROCK2 | |
| SCHEMBL6526399 | 0.82 | ROCK2 (0.51) | MAPTPIM2PIM3PIM1ROCK2 | |
| SCHEMBL19943253 | 0.82 | KDM4E (0.57) | MAPTPIM2PIM3PIM1KDM4E | |
| SCHEMBL6526402 | 0.82 | ROCK2 (0.51) | MAPTPIM2PIM3PIM1ROCK2 | |
| SCHEMBL13354904 | 0.80 | ROCK2 (0.50) | MAPTPIM2PIM3PIM1ROCK2 | |
| SCHEMBL14216365 | 0.80 | ROCK2 (0.50) | MAPTPIM2PIM3PIM1ROCK2 | |
| SCHEMBL14216367 | 0.80 | ROCK2 (0.50) | MAPTPIM2PIM3PIM1ROCK2 | |
| SCHEMBL21013405 | 0.79 | MAPT (0.45) | MAPTPIM2PIM3PIM1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202851-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | NOVARTIS AG (CH) | 2012-08-09 | — | — | US | disclosed |
| US-8168794-B2 | Pim kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2012-05-01 | — | — | US | disclosed |
| US-20100216839-A1 | Pim kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216839-A1 | Pim kinase inhibitors and methods of their use | PIM1, PIM2, PIM3 | MAPT 978/4885PIM2 2/4885PIM3 3/4885 |
| US-20120202851-A1 | PIM KINASE INHIBITORS AND METHODS OF THEIR USE | PIM1, PIM2, PIM3 | MAPT 978/4885PIM2 2/4885PIM3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.